Invizyne Technologies has entered the biomanufacturing industry with the successful launch of its initial public offering (IPO), which officially closed on November 14, 2024, generating gross proceeds of $15 million through the issuance of 1,875,000 shares at $8 per share. Trading under the ticker symbol “IZTC,” Invizyne’s shares debuted on the Nasdaq Capital Market on November 13, 2024.
Current Share Price:
Invizyne’s cell-free enzymatic system uses enzymes like skilled workers to efficiently assemble molecules, avoiding the limits of traditional cellular processes. By bypassing the cellular barriers common in synthetic biology, Invizyne aims to produce a wide array of commercially valuable chemicals — ranging from active pharmaceutical ingredients and biofuels to food flavors and cosmetics — more efficiently and sustainably.
SimplePath, Invizyne’s proprietary platform, transforms renewable resources into complex molecules, addressing inefficiencies and high costs of traditional methods like chemical synthesis and natural extraction.
SimplePath systems leverage cascades of enzymes — sequenced biochemical reactions — to efficiently transform raw materials into target compounds, offering a more scalable and sustainable alternative to traditional methods.
XTALKS WEBINAR: Enhancing Solid-Phase Peptide Synthesis with Green Chemistry Principles: A Step Towards Sustainability
Live and On-Demand: Tuesday, December 10, 2024, at 11am EST (4pm GMT/UK)
Register for this free webinar to explore innovative strategies for reducing solvent and reagent usage in solid-phase peptide synthesis while maintaining high-quality results.
Since its founding in 2019, Invizyne has focused on developing SimplePath for essential chemical production. Current projects include cannabigerolic acid, a precursor to cannabinoids with therapeutic potential, and isobutanol, a biofuel building block.
SimplePath’s approach enables near-theoretical yields, where most input material converts into the desired product with minimal waste. An article in Nature Communications revealed that using glucose as the input, Invizyne had achieved isobutanol production metrics that surpassed ethanol fermentation, reaching titers of up to 275 g/L and a 95 percent yield in extended, multi-day runs.
These initiatives were boosted with a $2 million project awarded under the Department of Defense’s (DoD’s) BioMADE initiative. This funding supports enzyme production for cell-free biomanufacturing of sustainable aviation fuel (SAF), a key component of the $27.4 billion global SAF market projected by 2032. By enabling scale-up in a 100L pilot facility, this project marks a critical step toward commercial viability and reinforces the versatility of SimplePath in renewable fuel production.
Related: Top 10 Most Environmentally Sustainable Pharma Companies in 2023/2024
BioMADE focuses on advancing US industrial biomanufacturing innovations and fostering workforce development to strengthen the country’s competitiveness in biotechnology. Conducted in partnership with the University of Georgia, the project builds on previous grants totaling $5.85 million from the US Department of Energy’s (DOE’s) Bioenergy Technologies Office (BETO) for developing isobutanol production.
Together, these efforts allow Invizyne to demonstrate the versatility of SimplePath’s enzyme-based systems, which could be applied across pharmaceuticals, biofuels, food additives and sustainable industrial chemicals.
With SimplePath at its core, Invizyne is on its way to shaping a greener, more efficient future.
Join or login to leave a comment
JOIN LOGIN